phase readout
savePhase 2 primary completion: BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
January 31, 2028updated 2d ago
community read0 votes
Sponsor: BioInvent International AB. Status: Recruiting. Conditions: Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma. NCT04752826.
view source ↗Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that